Abstract Details

Title Chronic Nausea/Vomiting as a Risk Factor for Restless Legs Syndrome in a Longitudinal Study of the American General Population

Topic Sleep

Presentation(s) Sleep Posters (7:00 AM-5:00 PM)

Poster/Presentation
Number 025

Background CNV, representing a diverse array of disorders, such as gastroparesis, defined by 4 weeks or more of symptoms, have been known to increase the likelihood of potassium deficiency. Since potassium plays a major role in regulating muscle contractions, it is possible that individuals suffering from CNV might be at a greater risk of experiencing Restless Legs Syndrome (RLS).

Objective To investigate whether Chronic Nausea and Vomiting (CNV) is a predictive factor of developing Restless Legs Syndrome (RLS).

Design/Methods This longitudinal study was carried out in eight states in the U.S. A total of 12,218 subjects representative of the general population were interviewed by phone during the first wave (W1) and 10,930 at the second wave (W2) three years apart. The analyses included only the subjects who participated in the 2 waves (N=10,930). RLS was defined according to the International Classification of Sleep Disorders.

Results CNV was reported by 3% (95% CI:2.7%-3.3%) of the sample at W1; nausea only was found in 9.8% (95% CI:9.2%-10.4%). CNV subjects were significantly younger (mean age of 45.6 vs. 52.7 years; p<0.001) and heavier (BMI, 30.2 vs. 27.8; p<0.001) than non-CNV participants. At follow-up (W2) 7.7% (95% CI:7.2%-8.2%) reported nausea only and 2.5% (95% CI:2.2%-2.8%) reported CNV, CNV was chronic in 25.7% of cases (present at W1 and W2). At W2, 2.5% (95% CI:2.2%-2.8%) of the sample reported RLS. After controlling for age, sex, BMI, health status and alcohol intake, individuals with CNV at W1 and W2 had a relative risk 7.5 times higher (95% CI:4.5-12.6; p<0.0001) of reporting RLS at W2 compared to subjects without CNV.

Conclusions CNV is associated with the development of RLS. Patients with GI disorders characterized by nausea/vomiting symptoms for years (e.g., gastroparesis) need attention to avoid the occurrence of RLS.

Authors/Disclosures
Maurice M. Ohayon, MD, PhD, DSc (Stanford) PRESENTER	The institution of Dr. Ohayon has received research support from Jazz pharmaceuticals. The institution of Dr. Ohayon has received research support from Takeda Pharmaceuticals.
	No disclosure on file
	No disclosure on file